[HLA class II typing in chronic myeloid leukemia with the complement fixation test using phytohemagglutinin-activated lymphocytes in the presence of interleukin 2 and gamma interferon].
In 23 cases of chronic myelogenous leukemia (CML) in remission, HLA class II typing was performed by complement fixation technique on phytohemagglutin (PHA) activated lymphocytes. In 10 cases satisfactory results were obtained, whereas in 13 cases the cells were weakly or non reactive, making impossible a correct determination of HLA-DR,DQ specificities. In the 13 cases a conditioned medium containing Interleukin-2 (Il-2) and gamma interferon (IFN) was added to PHA, inducing a good HLA class II reactivity and making possible a satisfactory definition of HLA-DR,DQ specificities. The complement fixation technique on lymphocytes cultured with PHA, Il-2 and gamma IFN made possible a correct HLA-DR,DQ typing in 23 consecutive cases of CML, while such a typing is often difficult or impossible when using the microlymphocytotoxicity technique on B lymphocyte targets.
Raffoux
C
C
Laboratoire d'Immunologie et d'Histocompatibilité, Hôpital Saint-Louis, Paris.
Lethielleux
P
P
Seguinard
M
M
Colombani
J
J
D000961:Antilymphocyte Serum / Q000276:immunology; D016026:Bone Marrow Transplantation; D003168:Complement Fixation Tests; D003601:Cytotoxicity Tests, Immunologic / Q000379:methods; D006683:HLA-DQ Antigens / Q000032:analysis; D006684:HLA-DR Antigens / Q000032:analysis; D006650:Histocompatibility Testing / Q000379:methods; D006801:Humans; D007371:Interferon-gamma; D007376:Interleukin-2; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology* / Q000601:surgery; D008213:Lymphocyte Activation; D010835:Phytohemagglutinins
D000961:Antilymphocyte Serum; D006683:HLA-DQ Antigens; D006684:HLA-DR Antigens; D007376:Interleukin-2; D010835:Phytohemagglutinins; D007371:Interferon-gamma
Typage HLA classe II des leucémies myéloïdes chroniques par la réaction de fixation du complément sur lymphocytes stimulés par la phytohémagglutinine en présence d'interleukine-2 et d'interféron gamma.